Endothelial exocytosis is an early stage in the process of leukocyte trafficking. N-ethylmaleimide-sensitive factor (NSF) plays a critical role in regulating exocytosis. We hypothesized that inhibitors of NSF decrease endothelial exocytosis and vascular inflammation. We designed a novel fusion polypeptide consisting of a human immunodeficiency virus transactivator of transcription (TAT) protein transduction domain joined to a NSF homohexamerization domain. We show that this TAT-NSF polypeptide inhibits the ATPase activity and the disassembly activity of NSF. Furthermore, the TAT-NSF polypeptide decreases endothelial cell exocytosis and reduces leukocyte adherence to endothelial cells in culture. Finally, the TAT-NSF polypeptide inhibits leukocyte rolling on murine venules in vivo and inhibits leukocyte trafficking into the peritoneal cavity in a murine model of experimental peritonitis. These data suggest that NSF is a critical regulator of leukocyte trafficking in vivo. Novel compounds that inhibit the exocytic machinery in endothelial cells may be useful anti-inflammatory drugs.
Exocytosis of endothelial cell granules is an important stage in leukocyte trafficking. Various inflammatory stimuli can trigger the release of granules from endothelial cells within minutes. These endothelial granules, termed WeibelPalade bodies (WPB), contain proteins that include von Willebrand's factor (vWF), which activates platelets and helps promote platelet aggregation and adhesion, and P-selectin, which mediates leukocyte rolling on vessel walls, allowing subsequent firm adhesion (Wagner, 1993) . P-selectin-null mice exhibit an absence of leukocyte rolling on an activated endothelium and a delayed recruitment of neutrophils to the peritoneal cavity following experimentally induced inflammation (Mayadas et al., 1993) . Following activation of endothelial exocytosis, further inflammatory stimuli can trigger leukocyte activation, which leads to expression of intracellular adhesion molecules mediating tight adherence to the vessel wall and diapedesis across the endothelium and into the tissue. However, endothelial exocytosis is the initial step in leukocyte trafficking.
Several sets of proteins mediate exocytosis, including Nethylmaleimide-sensitive factor (NSF), soluble NSF attachment receptors (SNAREs), Sec/Munc proteins, and members of the Rab superfamily (Rothman and Wieland, 1996; Jahn and Sudhof, 1999; Mellman and Warren, 2000; Wickner and Haas, 2000; Jahn et al., 2003) . SNAREs are transmembrane proteins associated with vesicle membranes and target membranes. Members of the SNARE superfamily include syntaxins, SNAP-25, and VAMP (or synaptobrevins) (Flaumenhaft et al., 1999) . The SNAREs expressed in endothelial cells include syntaxin-2, syntaxin-4, SNAP-23, and VAMP-3 (Matsushita et al., 2003) . Three members of the SNARE family can associate via coiled-coil SNARE domains, forming a stable ternary complex and bringing vesicle and target membranes into apposition. The original SNARE hypothesis of Rothman proposed that unique combinations of SNARE molecules specified membrane fusion partners.
Vesicle trafficking also requires NSF, a member of the ATPase-associated activity superfamily. NSF is comprised of three domains (Fig. 1A) (Wilson et al., 1992; Tagaya et al., 1993) . The N-terminal domain is responsible for NSF binding to the SNARE complex through the accessory protein ␣-sol-uble NSF attachment protein (␣-SNAP). The D1 domain contains an ATPase site; hydrolysis of ATP provides the energy for NSF disassembly activity (Whiteheart et al., 1994; Matveeva et al., 1997) . The D2 domain binds to ATP (without hydrolysis) and mediates hexamerization of NSF.
We hypothesized that inhibitors of NSF would decrease endothelial exocytosis, leukocyte trafficking, and tissue inflammation. We therefore developed a novel compound that can cross cell membranes and inhibit NSF. This NSF inhibitory compound is a fusion polypeptide consisting of two domains: an amino-terminal domain derived from HIV transactivator of transcription (TAT) protein fused to a carboxyterminal domain derived from NSF. The region of TAT that mediates cell penetration is an 11-amino acid residue sequence (YGRKKRRQRRR) (Frankel and Pabo, 1988; Green and Loewenstein, 1988; Green et al., 1989) . Mammalian cells internalize TAT-fusion polypeptides by a lipid raft-dependent, macropinocytosis-mediated process (Wadia et al., 2004) . Polypeptides consisting of this TAT domain fused to proteins can cross membranes of cells ex vivo and in vivo (Schwarze et al., 1999; Schwarze and Dowdy, 2000; Snyder and Dowdy, 2001 ; Vocero-Akbani et al., 2001). The carboxyterminal portion of the NSF inhibitor is derived from amino acid residues 700 to 722 of NSF. This region within the D2 domain of NSF mediates NSF homohexamerization. We refer to this fusion polypeptide as TAT-NSF700.
We used this novel fusion polypeptide to test the hypothesis that inhibition of endothelial cell exocytosis decreases leukocyte trafficking and inflammation. We now show, using a murine model of leukocyte rolling and peritonitis, that TAT-NSF700 decreases endothelial exocytosis in vitro, leukocyte adherence ex vivo, leukocyte rolling along venules in vivo, and leukocyte trafficking into the peritoneal cavity following experimentally induced inflammation. These data suggest that inhibitors of exocytosis are potentially valuable in the treatment of inflammatory disorders.
Materials and Methods
Peptide Design. TAT-NSF fusion peptides were synthesized by Anaspec (San Jose, CA). The peptide sequence of TAT-NSF700 was YGRKKRRQRRR-GGG-LLDYVPIGPRFSNLVLQALLVL, and TAT-NSF700scr was YGRKKRRQRRR-GGG-IPPVYFSRLDLNLVV-LLLAQL. Fig. 1 . TAT-NSF fusion polypeptide inhibits NSF. A, design of TAT-NSF700 polypeptide. A fusion polypeptide was synthesized that consists of 11 amino acids of the PTD of the HIV TAT protein, followed by a linker consisting of (Gly) 3 , followed in turn by 23 amino acids of NSF residues 700 to 722. B, TAT-NSF700 inhibits NSF ATPase activity. Recombinant NSF and ␣-SNAP were mixed with the TAT-NSF700 peptide or its control, and the ATPase activity of NSF was measured by a colorimetric assay (n ϭ 3 Ϯ S.D. ‫,ءء‬ P Ͻ 0.01 versus control). C, TAT-NSF700 inhibits disassembly activity of NSF. Recombinant NSF and ␣-SNAP were mixed with the TAT-NSF700 peptide or its control and then incubated with GST-SNARE fusion polypeptides (GST-syntaxin-4, GST-VAMP3, and GST-SNAP23). ATP or ATP-␥S was added, and the mixture was precipitated with glutathione-Sepharose. Precipitated proteins were immunoblotted with antibody to the NSF tag (repeated two times with similar results).
NSF ATPase Assay. The ATPase activity of NSF was measured by a coupled assay, in which ATP utilization is linked to the pyruvate kinase reaction, which generates pyruvate, which in turn is measured continuously with lactate dehydrogenase (Huang and Hackney, 1994) . Recombinant NSF (0.2 g/l) was pretreated with TAT-NSF700 or TAT-NSF700scr for 10 min at 22°C. ATPase reaction buffer (100 mM HEPES buffer, pH 7.0, 100 mM KCl, 10 mM MgCl 2 , 5 mM CaCl 2 , 10 mM ATP, 5 mM phosphoenol pyruvate, 50 U lactate dehydrogenase, and 50 U pyruvate kinase) was added to the mixture, followed by 10 l of NADH (2 mg/ml in 1% sodium bicarbonate). The mixture was incubated for 10 min at 22°C, and the absorbance was measured at 340 nm.
Disassembly Assay. The effect of TAT-NSF700 on SNARE complex disassembly activity of NSF was studied in vitro as described previously (Matsushita et al., 2003) . Recombinant (His) 6 -NSF, (His) 6 -␣-SNAP, GST-syntaxin-4, GST-VAMP3, and GST-SNAP23 were expressed in bacteria and purified. Recombinant NSF (0.5 g) was incubated with control, TAT-NSF700, or TAT-NSF700scr for 10 min and then added to equal amounts of ␣-SNAP, GST-syntaxin-4, GST-VAMP3, and GST-SNAP23. The incubation buffer was 4 mM HEPES, 0.1M NaCl, 1 mM EDTA, 3.5 mM CaCl 2 , and 0.5% NP40. Either 10 mM ATP or ATP-␥S with 20 mM MgCl 2 was added along with 50 l of binding buffer and 20 l of 50% glutathione-Sepharose beads. The mixture was incubated for 1 h at 4°C, washed in binding buffer, and boiled for 3 min with SDS sample buffer. Samples were fractionated on 4 to 15% precast gels (Bio-Rad, Hercules, CA) and immunoblotted.
Cell Exocytosis Studies. HAEC (Cambrex Bio Science Walkersville, Walkersville, MD) were incubated with TAT-NSF700 or control for 15 min and activated with 1 U/ml thrombin. vWF release was measured by an ELISA. In some experiments examining the persistence of the effects of TAT-NSF700, HAEC were washed after the 15-min incubation with TAT-NSF700 and then activated with thrombin 0 to 8 h after TAT-NSF700 treatment. Human platelets were acquired from normal healthy blood donors. Subjects were excluded if they had used aspirin or a nonsteroidal anti-inflammatory agent 10 days prior to the blood draw. Blood was collected by venipuncture into sodium citrate anticoagulant tubes. Whole blood was centrifuged at 180g for 15 min to isolate the top layer of platelet rich plasma. Platelets were incubated for 15 min with TAT-NSF700 or control and activated with TRAP (thrombin receptor-activating peptide). Surface P-selectin translocation was measured by FACS.
TAT-NSF700 Inhibition of Leukocyte Binding to Endothelial Cells. HAEC cells were grown in six-well plates. Cells were incubated with 1 M of TAT-NSF700, TAT-NSF700Scr, or control for 20 min. HAEC cells were activated with 1 U/ml of thrombin (SigmaAldrich, St. Louis, MO) or control for 20 min. Whole blood from human donors was collected into EDTA-containing tubes by venipuncture and fluorescently labeled with 50 l of 0.05% rhodamine 6G (Molecular Probes, Eugene, OR) in 3 ml of blood. Blood (25 l) was added to the cells for 20 min with gentle rocking. Cells were washed three times. Separate fields were imaged using a fluorescent microscope (Nikon, Melville, NY) and a digital imaging camera (Retiga, Burnaby, BC, Canada) for each experiment. The mean fluorescence was determined in each field. As a negative control, cells were also activated or not as above, and cells were incubated with anti-Pselectin antibody (BD Biosciences PharMingen, San Diego, CA) prior to the addition of leukocytes.
Leukocyte Rolling in Vivo. Intravital microscopy was performed as previously described . Leukocytes were fluorescently labeled with rhodamine 6G (50 l of 0.05%) intravenous. Mice were anesthetized with ketamine (80 mg/kg) and xylazine (13 mg/kg) and then injected intravenously with control, 0.5 mg/kg TAT-NSF700, or TAT-NSF700Scr. The mesentery was exteriorized, venules (120 -150 M diameter) were selected, and the mouse mesentery was prepared on an inverted fluorescent microscope (Nikon) with a 37°C stage warmer. Endothelial degranulation was induced by the superfusion of 30 l of 1 M histamine, and images of leukocyte rolling were captured each minute (Retiga). Leukocyte rolling on the activated endothelium was quantified at each time point.
Wall shear rate was measured by intravital microscopy according to the methods of others (Kubes et al., 1991; Scalia et al., 1996; Sperandio et al., 2003) . Erythrocytes were isolated from mice, labeled with calcein-acetoxymethyl ester, and injected into wild-type mice, which were then treated or not with TAT-NSF700. Erythrocyte velocity was measured by determining the distance traveled in a 50-ms period. Venule diameter was measured by direct observation using image analysis software. Wall shear rate was calculated as follows: g ϭ 8(erythrocyte velocity/venule diameter).
Peritonitis Model. C57BL6/J mice were injected intraperitoneally with 1 ml of 2% glycogen and intravenously with 0.5 mg/kg TAT-NSF700 peptide. After 2 or 4 h, the mice underwent a peritoneal lavage with 5 ml of a solution containing 0.1% albumin and 0.5 mM EDTA. One milliliter of lavage solution was withdrawn from the peritoneal cavity, centrifuged at 3000 rpm for 5 min, and resuspended in 250 l of solution. Cell counts were performed using a Coulter counter.
Statistical Analysis. Results are expressed as mean Ϯ standard deviation (S.D.). Comparison between groups was performed by Student's paired two-tailed t test. Two-way analysis of variance was used to describe differences between groups, with post hoc analysis performed by the methods of Student-Newman-Keuls. A value of P Ͻ 0.05 was considered significant.
Results

TAT-NSF Fusion Polypeptide Inhibits NSF.
We designed a fusion polypeptide that crosses cell membranes and inhibits NSF. The fusion polypeptide consists of two domains. The amino terminal domain consists of the HIV TAT protein transduction domain (PTD) amino acids 48 to 57. The carboxy terminal domain consists of amino acids 700 to 722 of NSF within the homohexamerization region of the D2 domain. The amino terminal TAT and carboxy terminal NSF fragments are linked by a poly-Gly linker. This peptide is designated TAT-NSF700. We also designed a control peptide designated TAT-NSF700scr, which consists of the intact TAT PTD, glycine poly-linker, and the same final 22 amino acids in a scrambled sequence (Fig. 1A) .
We first explored the effect of the fusion polypeptide TAT-NSF700 upon the ATPase activity of NSF. We synthesized recombinant (His) 6 -NSF and (His) 6 -␣-SNAP in bacteria and purified them using metal chelate chromatography. We then added TAT-NSF700 or its control, TAT-NSF700scr, to recombinant NSF and ␣-SNAP and measured ATPase activity using a coupled assay. TAT-NSF700 inhibits the ATPase activity of NSF in a dose-dependent manner as compared with its control peptide TAT-NSF700scr (Fig. 1B) . The IC 50 of TAT-NSF700 is between 0.1 to 1.0 M.
We next investigated TAT fusion peptide inhibition of NSF disassembly activity. TAT-NSF700 or TAT-NSF700scr was added to a mixture of recombinant NSF, ␣-SNAP, GST-syntaxin-4, GST-VAMP-3, and GST-SNAP-23. Glutathione beads were added to precipitate GST-tagged peptides, and the precipitate was immunoblotted against NSF. As expected, NSF cannot disassemble the SNARE complex in the presence of ATP-␥S (Fig. 1C, left panel) . Furthermore, NSF can disassemble the SNARE complex in the presence of ATP (Fig. 1C, left panel) . However, TAT-NSF700 dose-dependently inhibits the disassembly activity of NSF (Fig. 1C, left  panel) . The TAT-NSF700scr control peptide does not inhibit NSF Inhibitor Decreases Inflammation the disassembly activity of NSF (Fig. 1C, right panel) . These data demonstrate that TAT-NSF700 inhibits the ATPase and disassembly activities of NSF.
TAT-NSF700 Inhibits Exocytosis from HAEC. We next explored the effect of TAT-NSF700 upon endothelial cell exocytosis. HAEC were incubated with TAT-NSF700, TATNSF700scr, or media alone for 20 min and then activated with thrombin. Exocytosis was measured using an ELISA for vWF. Thrombin triggers HAEC release of vWF ( Fig. 2A) . TAT-NSF700 inhibits vWF release (Fig. 2A) . In contrast, the control peptide TAT-NSF700scr has no effect.
To explore whether or not TAT-NSF700 peptide inhibition of exocytosis is reversible, we treated endothelial cells with TAT-NSF700 for 15 min, washed the cells, and then activated the cells with thrombin at various times and measured vWF release. Thrombin alone activates exocytosis (Fig. 2B) . TAT-NSF700 inhibits exocytosis within 30 min of treatment (Fig. 2B) . The effects of TAT-NSF700 begin to wear off within 1 h after treatment. Within 2 h after TAT-NSF700 treatment, endothelial cells have complete recovery of exocytosis (Fig. 2B) . These data suggest that TAT-NSF700 inhibits exocytosis over a 2-h period, that treated cells recover the ability to undergo exocytosis, and that the peptide is not toxic to cells.
We also explored the effect of TAT-NSF700 upon platelet exocytosis. Platelets were incubated with control or TAT-NSF700 for 15 min and then activated with TRAP. Platelet granule exocytosis was measured by surface P-selectin translocation using FACS. TAT-NSF700 does not inhibit granule exocytosis from platelets (Fig. 2C) .
TAT-NSF700 Decreases Leukocyte Adherence to Endothelial Cells in Vitro. Since endothelial exocytosis externalizes P-selectin, which in turn contributes to leukocyte adherence, we predicted that inhibitors of endothelial exocy- Fig. 2 . TAT-NSF700 inhibits exocytosis of endothelial cells. A, TAT-NSF700 inhibits endothelial cell exocytosis: dose-response. HAEC were incubated with TAT-NSF700 or control and stimulated with thrombin 15 min afterward, and the concentration of vWF released into the media was analyzed by ELISA (n ϭ 3 Ϯ S.D.; ‫,ء‬ P Ͻ 0.05). B, TAT-NSF700 inhibits endothelial cell exocytosis: time-response. HAEC were incubated with 1 M TAT-NSF700 or nothing (control) at time 0 and stimulated at various times thereafter with thrombin, and the concentration of vWF released into the media was analyzed by ELISA (n ϭ 3 Ϯ S.D.; ‫,ء‬ P Ͻ 0.05). C, TAT-NSF700 does not inhibit platelet granule exocytosis. Platelets were incubated with TAT-NSF700 or control, activated with TRAP, and analyzed by FACS for surface P-selectin expression (n ϭ 3 Ϯ S.D.). tosis would decrease leukocyte adherence to endothelial cells. Accordingly, we next examined the effect of TAT-NSF700 upon leukocyte binding to endothelial cells in vitro. HAEC were incubated with TAT-NSF700, TAT-NSF700scr, or control. Endothelial cells were then activated with thrombin or not, and fluorescently labeled leukocytes were added. The cells were washed to remove nonadherent leukocytes, images of fluorescent adherent cells were taken, and the mean fluorescence of each condition was determined. Thrombin increases leukocyte binding to endothelial cells (Fig. 3, A and   B ). TAT-NSF700 inhibits leukocyte binding to stimulated endothelial cells (Fig. 3, A and B) . However, TAT-NSF700scr does not inhibit leukocyte binding to activated endothelial cells. These data demonstrate that the NSF inhibitor TAT-NSF700 decreases leukocyte binding to stimulated endothelial cells in culture.
P-selectin, a mediator of leukocyte-endothelial cell interactions, is delivered to the surface of endothelial cells by WPB exocytosis. To demonstrate that in our model system leukocyte binding to HAEC is mediated in part by P-selectin surface translocation, HAECs were prepared as above and activated or not with thrombin, and antibody to P-selectin was added following thrombin activation. Fluorescent leukocytes were added to HAEC cells and washed, and the number of adherent leukocytes was counted. Thrombin increases leukocyte binding to endothelial cells (Fig. 3C) . In contrast, antibody to P-selectin inhibits leukocyte binding to activated endothelial cells (Fig. 3C) . These data show that leukocyte binding to HAEC is at least partially dependent on P-selectin translocation.
TAT-NSF700 Inhibits Leukocyte Rolling in Vivo. We next investigated the in vivo effect of the TAT-NSF700 peptide using a model of leukocyte rolling in mice. Mice were injected with rhodamine 6G to fluorescently label leukocytes in vivo. Vehicle, TAT-NSF700, or TAT-NSF700scr (0.5 mg/ kg) were injected intravenously, and the mesentery was exteriorized on the stage of an inverted microscope. Endothelial cell Weibel-Palade body degranulation was induced by superfusion of 30 l of 1 M histamine. Images of rolling leukocytes on venules were captured using a digital camera. Histamine increases leukocyte rolling within 3 min of treatment (Fig. 4, A and B) . TAT-NSF700 inhibits leukocyte rolling. The TAT-NSF700scr control peptide has no effect upon histamine-activated leukocyte rolling (Fig. 4, A and B) . TAT-NSF700 has no effect on the vessel hemodynamics as assessed by measuring vessel diameter and erythrocyte velocity before and after histamine treatment (Table 1 ). These data demonstrate that TAT-NSF700 decreases leukocyte rolling in vivo.
We next explored the effect of TAT-NSF700 in a murine model of acute peritonitis. Following injection of TAT-NSF700, TAT-NSF700scr peptide, or control intravenously, mice were then injected intraperitoneally with 1 ml of 2% glycogen or control to induce peritonitis. The peritoneum was lavaged 2 and 4 h after glycogen treatment, and the number of leukocytes was counted. TAT-NSF700 decreases the number of leukocytes in the peritoneum following glycogen injury compared with control (Fig. 4C) . In particular, TAT-NSF700 decreases peritonitis within 2 h after glycogen treatment; however, the effect of TAT-NSF700 wears off, and it has no effect 4 h after glycogen treatment (Fig. 4C) . TAT-NSF700scr does not reduce leukocyte infiltrates into the peritoneum. The percentage of each cell type stays constant between treatment groups, with only the total number of leukocytes differing (data not shown). These data show that TAT-NSF700 decreases leukocyte translocation into the peritoneum following experimental peritoneal inflammation.
We then administered the TAT-NSF700 peptide after glycogen treatment to see if this peptide could alter the course of peritonitis after inflammatory insults. Mice were injected i.p. with glycogen at time 0 and treated with TAT-NSF700 peptide 1 or 2 h after glycogen. Mice were then lavaged 4 h after Fig. 3 . TAT-NSF700 decreases leukocyte adherence to endothelial cells in culture. A, endothelial cells were treated with control, TAT-NSF700scr, or TAT-NSF700 for 20 min and then activated with 1 U/ml of thrombin for 30 min. Rhodamine 6G-labeled human leukocytes were then added, and the mixture was rocked at 22°C for 10 min and washed three times. A digital camera collected multiple images at 4ϫ of fluorescently labeled adherent cells (representative from nine fields). B, endothelial cells were treated as above, and mean fluorescence was measured by a digital camera (n ϭ three fields from each of three wells Ϯ S.D.; ‫,ء‬ P Ͻ 0.05 versus thrombin). C, P-selectin antibody decreases leukocyte adherence to endothelial cells in vitro. Endothelial cells were activated with 1 U/ml control or thrombin for 20 min, and then antibody to P-selectin or control was added for 20 min. The adhesion of rhodamine 6G-labeled human leukocytes to endothelial cells was measured as above (n ϭ three fields from each of three wells Ϯ S.D.; ‫,ء‬ P Ͻ 0.05 versus thrombin).
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at ASPET Journals on May 12, 2017 jpet.aspetjournals.org glycogen treatment, and the number of leukocytes was counted. TAT-NSF700 administered 2 h after glycogen decreases inflammation (Fig. 4D) . However, TAT-NSF700 has no effect on inflammation when administered 1 h after glycogen. These data suggest that TAT-NSF700 administered as a single i.v. bolus can suppress exocytosis over a 2-h period.
Together, these data demonstrate that the novel peptide inhibitor of NSF TAT-NSF700 reduces endothelial WeibelPalade body exocytosis, leukocyte rolling, and adherence in vitro and in vivo.
Discussion
The major findings of our study are that a novel fusion polypeptide inhibits NSF, endothelial exocytosis, leukocyte adherence to endothelial cells, leukocyte rolling in vivo, and peritonitis. These data show that NSF is a key molecule that regulates leukocyte trafficking in vivo and also show that compounds that inhibit NSF may be novel anti-inflammatory drugs.
Our data suggest that endothelial exocytosis is critical for leukocyte trafficking. Various knockout mice lacking WPB components demonstrate the importance of endothelial exocytosis to cell trafficking. Knockout mice lacking vWF display severe defects in hemostasis and thrombosis, whereas Pselectin-deficient mice exhibit compromised leukocyte rolling and extravasation (Mayadas et al., 1993; Denis et al., 1998) . TAT-NSF700-treated mice have a functional phenotype very similar to P-selectin knockout mice (Fig. 4) . Studies utilizing anti-adhesion molecule therapies also demonstrate the importance of WPB components in regulating leukocyte and endothelial cell interactions. Monoclonal antibodies to Pselectin or its ligand or other adhesion molecules decrease vascular inflammation and tissue injury, particularly in models of inflammatory bowel disease, multiple sclerosis, and psoriasis (Harlan and Winn, 2002) . TAT-NSF700 similarly decreases P-selectin-mediated leukocyte adherence to endothelial cells (Fig. 3) ; however, clinical trials of antiadhesion molecule therapy aimed at ischemia-reperfusion have been less fruitful (Harlan and Winn, 2002; Yonekawa   Fig. 4 . TAT-NSF700 inhibits leukocyte rolling in vivo. A, effects of TAT-NSF700 on leukocyte rolling in vivo. Mice were anesthetized and injected with rhodamine 6G to label leukocytes. The mesentery was externalized, and venules 120 to 150 m in diameter were treated with 1 M histamine. Leukocyte rolling on venules was imaged with a digital fluorescent camera after histamine treatment from 0 to 10 min (representative images from n ϭ 4 -5 mice). B, quantitation of effects of TAT-NSF700 on leukocyte rolling in vivo. Mice were treated with TAT-NSF peptides and injected with fluorescent leukocytes, and the number of leukocytes rolling on histamine-treated venules was measured as above (n ϭ 4 -5 mice per group Ϯ S.E.M. ‫,ء‬ P Ͻ 0.05 versus TAT-700scr). C, TAT-NSF700 reduces leukocyte infiltration in peritonitis. Mice were injected with glycogen or control i.p., and some mice were injected with TAT-NSF peptides. After 2 and 4 h, the peritoneum was lavaged, and the number of inflammatory cells was measured with a Coulter counter (n ϭ 5-7 Ϯ S.D. ‫,ء‬ P Ͻ 0.05 versus TAT-NSF700Scr). D, TAT-NSF700 reduces leukocyte infiltration in peritonitis. Mice were injected with glycogen i.p. at time 0 h. TAT-NSF700 peptide was administered i.v. 1 or 2 h after glycogen. At 4 h after glycogen administration, the peritoneum was lavaged, and the number of inflammatory cells was measured with a Coulter counter (n ϭ 5-7 Ϯ S.D.; ‫,ء‬ P Ͻ 0.05 versus controls). Harlan, 2005) . A possible reason for the lack of benefit is that many of these therapies target events following endothelial exocytosis, such as expression of individual intercellular adhesion molecules or isolated integrins on leukocytes and endothelial cells. Our TAT-NSF700 peptide may provide a means to target acute inflammatory events and suppress endothelial cell inflammatory activation. We found that TAT fusion polypeptides will enter endothelial cells but not platelets. No previous studies have identified a cell type into which TAT polypeptides cannot enter. TAT PTD-mediated uptake was initially thought to occur by direct penetration across the cell membrane. However, a recent study by Wadia indicates that cellular uptake of TATfusion protein is mediated by rapid TAT internalization through lipid raft-dependent macropinocytosis (Wadia et al., 2004) . Platelets also take up proteins from their surroundings by endocytic mechanisms. Platelet endocytosis is part of granule maturation. Platelet granules acquire much of their protein content by endocytosis and pinocytosis in both megakaryocytes and platelets (Harrison and Cramer, 1993) . Our finding that platelets cannot take up TAT-NSF700 suggests that platelets lack lipid raft-dependent macropinocytosis. Alternatively, our data may indicate that TAT PTD uptake is mediated by a receptor present in the lipid raft-rich membrane domain of some cells, such as endothelial cells, but absent from other cells, such as platelets.
We designed TAT-NSF700 to interact with the hexamerization domain of endogenous NSF. We hypothesize that our peptide is a dominant negative inhibitor of NSF, interfering with NSF assembly into homohexamers. The reversibility of TAT-NSF700 may be related to dynamic NSF hexamerization or synthesis of new NSF molecules.
The effects of a single dose of TAT-NSF700 are brief: TAT-NSF700 inhibits exocytosis of cultured cells for 0 to 2 h after treatment (Fig. 2B) . The peptide may be degraded by cell proteolytic pathways. TAT-NSF700 also inhibits inflammation for a brief period in vivo: the peptide inhibits inflammation within 2 h of treatment but has no effect 4 h after treatment (Fig. 4C) . The catabolic pathways of TAT-tagged peptides are unknown.
Our data and the work of others suggest that NSF is a critical regulator of endothelial exocytosis. Since endothelial exocytosis regulates leukocyte trafficking, novel inhibitors of NSF may prove useful in the treatment of inflammatory diseases.
